WithdrawnNCT05344365
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Medication studyAges 65+United StatesSchizophrenia
Understand this study
Who could participate?
Listed age limits: from 65 years.
- Listed locations
- St. PetersburgSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: June 2022
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Vanda Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 65 Years
- Official registry ID
- NCT05344365
- Official title
Show the full official title
An Open-label, Sequential Cohorts, Flexible Dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Iloperidone in Elderly Patients With Parkinson's Disease Psychosis (PDP)
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
St. Petersburg
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vanda Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including Iloperidone.
Who can participate?
Listed age limits: from 65 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
